4117 Stock Overview
Engages in the research, development, manufacture, and sales of in-vitro diagnostics in Taiwan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
General Biologicals Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$19.45 |
| 52 Week High | NT$26.95 |
| 52 Week Low | NT$16.20 |
| Beta | 1.5 |
| 1 Month Change | 17.88% |
| 3 Month Change | 1.30% |
| 1 Year Change | -26.33% |
| 3 Year Change | -49.41% |
| 5 Year Change | 70.17% |
| Change since IPO | 89.76% |
Recent News & Updates
Shareholder Returns
| 4117 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 5.1% | 1.5% | -0.7% |
| 1Y | -26.3% | 4.6% | 28.8% |
Return vs Industry: 4117 underperformed the TW Biotechs industry which returned 4.6% over the past year.
Return vs Market: 4117 underperformed the TW Market which returned 28.8% over the past year.
Price Volatility
| 4117 volatility | |
|---|---|
| 4117 Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 4.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4117's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 4117's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1973 | n/a | T.C. Lin | www.gbc.com.tw |
General Biologicals Corporation engages in the research, development, manufacture, and sales of in-vitro diagnostics in Taiwan and internationally. It offers ELISA and chemiluminescence immunoassay, molecular and cell diagnostic, and point of care testing services. The company also provides COVID-19, digital pathology, and contract development manufacturing organization solutions; blood screening services for hepatitis and HIV; and biomaterial, such as antibody biomaterials and human plasma.
General Biologicals Corporation Fundamentals Summary
| 4117 fundamental statistics | |
|---|---|
| Market cap | NT$1.18b |
| Earnings (TTM) | -NT$209.31m |
| Revenue (TTM) | NT$242.40m |
4.9x
P/S Ratio-5.7x
P/E RatioIs 4117 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4117 income statement (TTM) | |
|---|---|
| Revenue | NT$242.40m |
| Cost of Revenue | NT$188.67m |
| Gross Profit | NT$53.73m |
| Other Expenses | NT$263.04m |
| Earnings | -NT$209.31m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.44 |
| Gross Margin | 22.16% |
| Net Profit Margin | -86.35% |
| Debt/Equity Ratio | 344.3% |
How did 4117 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 01:13 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
General Biologicals Corporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Li-chun Chang | Jih Sun Securities Investment Consulting Co., Ltd. |